GP 515

Known as: 4-amino-1-(5-amino-5-deoxy-1-ribofuranosyl)-3-bromopyrazolo(3,4-d)pyrimidine, GP-515 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
AbstractBackground: Microcirculatory perfusion failure, known as the “no-reflow phenomenon”, often develops within a few days… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2000
2000
We tested whether increased endogenous adenosine produced by the adenosine kinase inhibitor GP-515 (Metabasis Therapeutics) can… Expand
Is this relevant?